CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019--
Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene
therapy company, today announced that the Company will present at the
Cowen and Company 39th Annual Health Care Conference onWednesday, March 13, 2019, at 8:40 a.m. ET at the Marriott Copley Place
Geoff MacKay, AVROBIO’s President and Chief Executive Officer, will
provide an overview of the Company and a business update. A live webcast
of the presentation will also be available under "Events and
Presentations" in the Investors section of the Company's website at www.avrobio.com.
An archived webcast recording of the event will be available on the
website for approximately 30 days.
About AVROBIO, Inc.
Inc., is a Phase 2 clinical-stage gene therapy company developing
gene therapies to potentially cure rare diseases with a single dose.
gene therapies employ hematopoietic stem cells that are collected
from the patient and then modified with a lentiviral vector to insert
functional copies of the gene that is defective in the target disease.
AVROBIO is focused on the development of its gene therapy, AVR-RD-01, in Fabry
disease, as well as additional investigational gene therapy programs
including in Gaucher disease, cystinosis and Pompe disease. The
Company’s plato™ platform incorporates a vector system and an automated,
closed, cell manufacturing solution designed to enable worldwide
commercialization. AVROBIO is headquartered in Cambridge, MA and has
offices in Toronto, ON. For additional information, visit www.avrobio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005349/en/
Source: AVROBIO, Inc.
Christopher F. Brinzey
The Yates Network